TY - JOUR
T1 - The management of elderly patients with brain metastases from breast cancer
AU - Ruiz-Garcia, Henry
AU - Marenco-Hillembrand, Lina
AU - Peterson, Jennifer L.
AU - Tzou, Katherine
AU - Malouff, Timothy D.
AU - Chaichana, Kaisorn L.
AU - Trifiletti, Daniel M.
AU - Vallow, Laura
N1 - Publisher Copyright:
© 2020 Translational Cancer Research. All rights reserved.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Breast cancer is the most common type of malignancy diagnosed in women worldwide, as well as the second most common cause of metastatic brain lesions in the general population. Most breast cancer patients enrolled in clinical trials are relatively young. Elderly patients, as compared to their younger counterparts, pose unique clinical scenarios because there is limited data in this subpopulation of patients with brain metastases from breast cancer. Elderly patients are commonly treated with less aggressive therapies, perhaps due to comorbid conditions, patient preference, or other age-related concerns. Current treatment modalities offering more favorable toxicity profiles, along with more accurate prognosis, can represent an opportunity to offer improved care for this patient population. From the few efforts studying brain metastatic disease in the elderly, it is be possible to infer that age alone may not play an independent role in treatment selection and that a patient-specific evaluation and ultimate clinical judgment should guide clinical decision-making.
AB - Breast cancer is the most common type of malignancy diagnosed in women worldwide, as well as the second most common cause of metastatic brain lesions in the general population. Most breast cancer patients enrolled in clinical trials are relatively young. Elderly patients, as compared to their younger counterparts, pose unique clinical scenarios because there is limited data in this subpopulation of patients with brain metastases from breast cancer. Elderly patients are commonly treated with less aggressive therapies, perhaps due to comorbid conditions, patient preference, or other age-related concerns. Current treatment modalities offering more favorable toxicity profiles, along with more accurate prognosis, can represent an opportunity to offer improved care for this patient population. From the few efforts studying brain metastatic disease in the elderly, it is be possible to infer that age alone may not play an independent role in treatment selection and that a patient-specific evaluation and ultimate clinical judgment should guide clinical decision-making.
KW - Brain metastases
KW - Breast cancer
KW - Elderly
KW - Management
KW - Radiation
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85078982044&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078982044&partnerID=8YFLogxK
U2 - 10.21037/tcr.2019.07.31
DO - 10.21037/tcr.2019.07.31
M3 - Review article
AN - SCOPUS:85078982044
SN - 2218-676X
VL - 9
SP - S62-S76
JO - Translational Cancer Research
JF - Translational Cancer Research
ER -